Table 2.
Toxicity, response, and outcome data
| Characteristic | All patients (n = 100) | PMF (n = 50) | PPV-MF (n = 27) | PET-MF (n = 23) |
|---|---|---|---|---|
| Grade 3/4 hematologic toxicity | ||||
| Grade 3/4 anemia | 36 (36) | 21 (42) | 6 (22) | 9 (39) |
| Grade 3/4 thrombocytopenia | 23 (23) | 11 (22) | 4 (15) | 8 (35) |
| Grade 3/4 neutropenia | 2 (2) | 2 (4) | 0 (0) | 0 (0) |
| Best IWG-MRT response over 48 wk | ||||
| Clinical improvement | 27 (27) | 14 (28) | 6 (22) | 7 (30) |
| Spleen response | 18 (18) | 8 (16) | 6 (22) | 4 (17) |
| Anemia response | 1 (1) | 0 (0) | 0 (0) | 1 (4) |
| Stable disease | 52 (52) | 28 (56) | 13 (48) | 11 (48) |
| Progressive disease | 1 (1) | 0 (0) | 1 (4) | 0 (0) |
| Not available | 1 (1) | 0 (0) | 1 (4) | 0 (0) |
| IWG-MRT spleen response over 48 wk | 41 (41) | 22 (44) | 9 (35) | 10 (45) |
| IWG-MRT anemia response over 48 wk | 11 (11) | 3 (6) | 5 (19) | 3 (13) |
| Transformation to accelerated/blast phase | 9 (9) | 3 (6) | 3 (11) | 3 (13) |
| Median TTF, wk | 116 | 100 | 149 | 119 |
| Median OS, wk | 182 | 172 | 226 | 143 |
All values expressed as n (%), unless otherwise indicated. No P value was found to be statistically significant between MF subtypes.